fotografixx / iStockphoto.com
The creator of OmniRat, the first human monoclonal antibody technology based on rats, outlined the success story of the project yesterday at the 2017 BIO International Convention.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
BIO 2017, OmniRat, patent, patentability, European Patent Office, licensing, Ligand Pharmaceuticals, antibodies, genetic engineering,
